A Randomized, Controlled Study To Investigate The Efficacy, Safety And Pharmacokinetics Of Legalon Sil, Alone Or In Combination With Ribavirin, For The Prevention Of Recurrent Hepatitis C In Liver Transplant Recipients.
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2015
At a glance
- Drugs Silibinin (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Rottapharm Madaus
- 10 Jan 2015 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
- 22 Apr 2014 New trial record